175 related articles for article (PubMed ID: 31336364)
1. Somatostatin receptor expression in parathyroid neoplasms.
Storvall S; Leijon H; Ryhänen E; Louhimo J; Haglund C; Schalin-Jäntti C; Arola J
Endocr Connect; 2019 Aug; 8(8):1213-1223. PubMed ID: 31336364
[TBL] [Abstract][Full Text] [Related]
2. Defining a molecular phenotype for benign and malignant parathyroid tumors.
Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
[TBL] [Abstract][Full Text] [Related]
3. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
[TBL] [Abstract][Full Text] [Related]
4. Expression of somatostatin receptors in peritumoral veins of human tumors.
Denzler B; Reubi JC
Cancer; 1999 Jan; 85(1):188-98. PubMed ID: 9921992
[TBL] [Abstract][Full Text] [Related]
5. Oxyphil parathyroid carcinomas: a clinicopathologic and immunohistochemical study of 10 cases.
Erickson LA; Jin L; Papotti M; Lloyd RV
Am J Surg Pathol; 2002 Mar; 26(3):344-9. PubMed ID: 11859206
[TBL] [Abstract][Full Text] [Related]
6. Deoxyribonucleic acid cytometry helps identify parathyroid carcinomas.
Levin KE; Chew KL; Ljung BM; Mayall BH; Siperstein AE; Clark OH
J Clin Endocrinol Metab; 1988 Oct; 67(4):779-84. PubMed ID: 3417849
[TBL] [Abstract][Full Text] [Related]
7. Overview of the 2022 WHO Classification of Parathyroid Tumors.
Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
[TBL] [Abstract][Full Text] [Related]
8. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
Juhlin CC; Nilsson IL; Johansson K; Haglund F; Villablanca A; Höög A; Larsson C
Endocr Pathol; 2010 Sep; 21(3):166-77. PubMed ID: 20473645
[TBL] [Abstract][Full Text] [Related]
9. Molecular Characteristics of Large Parathyroid Adenomas.
Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis.
Stojadinovic A; Hoos A; Nissan A; Dudas ME; Cordon-Cardo C; Shaha AR; Brennan MF; Singh B; Ghossein RA
Hum Pathol; 2003 Jan; 34(1):54-64. PubMed ID: 12605367
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.
Sulaiman L; Haglund F; Hashemi J; Obara T; Nordenström J; Larsson C; Juhlin CC
PLoS One; 2012; 7(9):e46325. PubMed ID: 23029479
[TBL] [Abstract][Full Text] [Related]
12. The thyroid and parathyroid glands. CT and MR imaging and correlation with pathology and clinical findings.
Weber AL; Randolph G; Aksoy FG
Radiol Clin North Am; 2000 Sep; 38(5):1105-29. PubMed ID: 11054972
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide analysis of differentially expressed lncRNA in sporadic parathyroid tumors.
Jiang T; Wei BJ; Zhang DX; Li L; Qiao GL; Yao XA; Chen ZW; Liu X; Du XY
Osteoporos Int; 2019 Jul; 30(7):1511-1519. PubMed ID: 30972448
[TBL] [Abstract][Full Text] [Related]
14. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors.
Cetani F; Marcocci C; Torregrossa L; Pardi E
Endocr Relat Cancer; 2019 Jul; 26(7):R441-R464. PubMed ID: 31085770
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia.
Levin KE; Galante M; Clark OH
Surgery; 1987 Jun; 101(6):649-60. PubMed ID: 3589961
[TBL] [Abstract][Full Text] [Related]
16. Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma.
Delellis RA
Endocr Pathol; 2008; 19(4):221-5. PubMed ID: 19058032
[TBL] [Abstract][Full Text] [Related]
17. Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas.
Cetani F; Pardi E; Banti C; Collecchi P; Viacava P; Borsari S; Fanelli G; Naccarato AG; Saponaro F; Berti P; Miccoli P; Pinchera A; Marcocci C
Endocr Relat Cancer; 2010 Mar; 17(1):1-6. PubMed ID: 19755524
[TBL] [Abstract][Full Text] [Related]
18. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors.
Vargas MP; Vargas HI; Kleiner DE; Merino MJ
Mod Pathol; 1997 Jan; 10(1):12-7. PubMed ID: 9021722
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of p53 immunoexpression in parathyroid hyperplasias secondary to uremia, primary hyperplasias, adenomas and carcinomas.
Kayath MJ; Martin LC; Vieira JG; Roman LM; Nosé-Alberti V
Eur J Endocrinol; 1998 Jul; 139(1):78-83. PubMed ID: 9703382
[TBL] [Abstract][Full Text] [Related]
20. Role of octreotide on release of intact 1-84 parathyroid hormone from human parathyroid cells.
Sadler GP; Jones DL; Morgan JM; Neonakis E; Woodhead JS; Wheeler MH
Br J Surg; 1998 Aug; 85(8):1133-7. PubMed ID: 9718014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
